Director's Letter
  SNPets from CDC
  Appendix A
  Appendix B
  List of Authors

Chapter 1
The Role of Human Genomics in Acute Public Health Investigations:
Current Practice and Future Strategies
Incorporating Human Genomics into Acute Public Health Investigations • Examples of Investigations • APHI Workshop Held in May 2004 • Conclusions from APHI Workshop • Current Public Health Research Priorities

Chapter 2
CDC’s Family History Public Health Initiative: 2005 Update
Family History for the Public • U.S. Surgeon General’s Family History Initiative • MMWR • Family Healthware™ • Evaluation Study • Public Health Research

Chapter 3
Genomics and Vaccine Safety: Research for Future Practice
Need for Vaccine Safety Research • Current Vaccine Safety Research at CDC • Integrating Genomics into Vaccine Safety Studies • The Future of Genomics and Vaccine Safety

Chapter 4
Direct-to-Consumer Marketing Campaign: Genetic Testing for Susceptibility to Breast and Ovarian Cancer
The Direct-to-Consumer Marketing Campaign • Public Health Significance • The Complexity of BRCA1 and BRCA2 Testing • BRCA1 and BRCA2 Tests Are Not Appropriate for Most Women • Direct-to-Consumer Advertising • Public Health Response • Survey Development • Consumer Survey Results • Provider Survey Results • Conclusions

Chapter 5
ACCE Reviews of Genetic Tests: BRCA1, BRCA2, and CFTR
Introduction to ACCE • The ACCE Review Process • Family History and BRCA1 and BRCA2 Mutation Testing to Identify Women at Risk for Inherited Breast/Ovarian Cancer • Preconception and Prenatal Screening for Cystic Fibrosis via CFTR Carrier Testing • Lessons Learned

Chapter 6
Evaluation of Genomic Applications in Practice and Prevention: Implementation and Evaluation of a Model Approach
What is the EGAPP Project? • The ACCE Project • Why is Evaluation of Emerging Genomic Applications a Public Health Issue? • EGAPP Working Group • Stakeholders • Other EGAPP Activities • Expert Meeting on Evidence-Based Review of Genomic Applications • Why Might EGAPP Project Activities Interest State and Local Public Health Professionals? • How Will Success Be Measured?

Chapter 7
Newborn Screening for Cystic Fibrosis: A Public Health Response
What is Cystic Fibrosis? • Why Test Newborns for Cystic Fibrosis? • Public Health Response • Weighing the Costs and Benefits for Universal Newborn Screening for CF • Adding CF Screening to Existing Newborn Screening Programs • Challenges in Implementing CF Screening • Laboratory Implementation Issues • Follow-up and Communication Issues • Conclusion

Chapter 8
Enhancing Genetic Testing for Rare Diseases: Improving Availability, Access, and Quality
Genetic Testing for Rare Diseases • What is a Rare Disease? • Public Health Implications of Improving the Translation of Rare Disease Genetic Testing • Promoting Quality Laboratory Testing for Rare Diseases: Keys to Ensuring Quality Genetic Testing • Public Health Actions: Improving the Translation of Tests for Rare Diseases from Research to Clinical Practice • Public Health Actions: Ensuring Access and Quality of Rare Disease Testing

Chapter 9
Centers for Genomics and Public Health: An Update
University of Michigan Center for Genomics and Public Health • University of North Carolina Center for Genomics and Public Health • University of Washington Center for Genomics and Public Health • Centers’ Collaborative Activities • Summary of the Centers’ Activities

Chapter 10
Developing State Capacity for Integrating Genomics into Chronic Disease Prevention Programs: An Update
Michigan Department of Community Health • Minnesota Department of Health Chronic Disease Genomics Project • Oregon State Genetics Program • Utah Department of Health: Chronic Disease Genomics Program • Summary of the States’ Activities